Sandoz Pty Limited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Sandoz Pty Limited Pharmaceutical Import Records from India — 7 Products, $6.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sandoz Pty Limited — Pharmaceutical Importer Profile (2026) | 7 Products, $6.2M Trade | TransData Nexus

Sandoz Pty Limited

Pharmaceutical Importer · Australia · Immunosuppressants Focus · $6.2M Total Trade · DGFT Verified

Sandoz Pty Limited is a pharmaceutical importer based in Australia with a total trade value of $6.2M across 7 products in 5 therapeutic categories. Based on 152 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sandoz Pty Limited sources from 7 verified Indian suppliers, with Cipla Limited accounting for 40.1% of imports.

Sandoz Pty Limited — Import Portfolio & Supplier Network

Sandoz Pty Limited import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sandoz Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$2.5M	307	40.1%
Sandoz Private Limited	$2.1M	70	33.6%
Intas Pharmaceuticals Limited	$1.3M

What Formulations Does Sandoz Pty Limited Import?

Formulation	Value	Ships
Allopurinol sdz 300MG 60tab bo v2 au	$256.8K	6
Salplusf inhaler 125/25 fluticasone	$200.0K	4
Salplusf inhaler 250/25 fluticasone	$200.0K	4
Metformin sandoz 500MG tabmetformin	$169.2K	6
Paracetamol sandoz pharma tablet 500 MG	$151.0K	5
Material no. - 44101010 sitaglip+metf sdz 50+1000MG 56prt bo	$144.0K	3
Allopurinol sdz 100MG 200tab bo v2 au material no. -	$136.1K	3
Valaciclovir sdz 500MG 30fct v2 au material no. -	$135.4K	3
Wagner health childrens ibuprofen 6 months - 12 year ibuprofen oral suspensionbp 100 MG / 5ML	$134.2K	10
Sandoz lamotrigine 50 MG tablets	$119.1K	5
Material no. - 44023521 topiramate sdz 50MG 60tab bo	$112.6K	4
Meloxicam sandoz 15 MG tablet. document	$108.9K	8
Metformin sandoz 500MG TAB metformin	$108.2K	4
Material no: 44091837 allopurinol sdz	$100.0K	2
Phrm drug&med:clopidogrel sandoz 75MG	$100.0K	2

Sandoz Pty Limited imports 202 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tacrolimus	Immunosuppressants	$1.9M	37	0.9%	12
2	Escitalopram	CNS & Psychiatric	$1.4M	27	0.7%	15
3	Mycophenolate	Immunosuppressants	$750.0K	15	0.2%	17
4	Allopurinol	Lipid & Metabolism	$700.0K	14	0.1%	9
5	Fluticasone	Respiratory	$650.0K	13	0.3%	9
6	Meloxicam	Analgesics & Antipyretics	$479.5K	37	0.2%	10
7	Salmeterol	Respiratory	$450.0K	9	0.6%	4

Sandoz Pty Limited imports 7 pharmaceutical products across 5 categories into Australia totaling $6.2M.

Sandoz Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sandoz Pty Limited is an Australian proprietary company, limited by shares, incorporated on 23 October 1996. (creditorwatch.com.au) It operates as a pharmaceutical importer and buyer, specializing in the acquisition of finished pharmaceutical formulations from international suppliers, particularly from India. The company is a subsidiary of Sandoz International GmbH, a global leader in generic pharmaceuticals and biosimilars, which is part of the Novartis Group. Sandoz Pty Limited plays a significant role in Australia's pharmaceutical distribution network by sourcing a diverse range of medicines to meet the country's healthcare needs.

2Distribution Network

While specific details about Sandoz Pty Limited's warehouse locations and logistics capabilities are not publicly disclosed, as a subsidiary of Sandoz International GmbH, it is likely integrated into the global distribution network of the Novartis Group. This integration suggests access to advanced logistics infrastructure and a broad geographic coverage within Australia and potentially beyond. The company's operations are designed to ensure a reliable supply chain, facilitating the efficient distribution of pharmaceutical products to various healthcare providers across the region.

3Industry Role

Sandoz Pty Limited functions primarily as a pharmaceutical importer and buyer within Australia's supply chain. It sources finished pharmaceutical formulations from international suppliers, particularly from India, to meet the domestic demand for various therapeutic products. By importing a diverse range of medicines, the company contributes to the availability and accessibility of essential pharmaceuticals in the Australian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sandoz Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sandoz Pty Limited's sourcing strategy exhibits a high degree of concentration, with the top five products accounting for 85.1% of its total import value. This concentration indicates a strategic focus on specific therapeutic areas, which may enhance operational efficiencies and strengthen supplier relationships. However, such dependency also poses risks, including potential supply chain disruptions if any of these key products face shortages or regulatory challenges. The company's reliance on a limited number of suppliers for these products suggests a need for robust contingency planning to mitigate potential risks associated with supplier dependency.

2Supply Chain Resilience

Sandoz Pty Limited's supply chain resilience is influenced by its sourcing patterns, particularly the concentration on a few key products and suppliers. The company's reliance on a limited number of suppliers for its top products suggests a need for robust contingency planning to mitigate potential risks associated with supplier dependency. Ensuring that all suppliers adhere to Good Manufacturing Practice (GMP) standards is crucial for maintaining the quality and safety of imported pharmaceuticals. Additionally, diversifying the supplier base and incorporating a broader range of formulations could enhance supply chain resilience by reducing dependency on specific suppliers and products.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of pharmaceutical imports is overseen by the Therapeutic Goods Administration (TGA), which operates under the Therapeutic Goods Administration Act 1989. The TGA is responsible for assessing the safety, quality, and efficacy of medicines before they can be supplied in Australia. Pharmaceutical products must be entered into the Australian Register of Therapeutic Goods (ARTG) before they can be legally imported, unless they are exempt from this requirement. (tga.gov.au)

2Import Licensing & GMP

Importers of therapeutic goods into Australia must comply with specific licensing requirements. Generally, therapeutic goods must be entered into the ARTG before they can be legally imported. Additionally, the TGA requires that all medicines be manufactured in accordance with Good Manufacturing Practice (GMP) standards to ensure their quality, safety, and efficacy. Overseas manufacturers must be certified by the TGA or another medicine regulator that applies the same requirements and standards as the TGA. (tga.gov.au)

3Quality & Labeling

Sandoz Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sandoz Pty Limited's focus on importing products in the immunosuppressants, CNS & psychiatric, and respiratory therapeutic categories aligns with market demand for these essential medicines. The company's import data indicates a strategic emphasis on these areas, suggesting a commitment to addressing critical healthcare needs in Australia. By concentrating on these therapeutic categories, Sandoz aims to provide a reliable supply of vital medications to healthcare providers and patients.

2Sourcing Profile

Sandoz Pty Limited's sourcing strategy involves importing finished pharmaceutical formulations from international suppliers, particularly from India. The company's focus on specific therapeutic areas reflects a strategic approach to meet the demand for essential medicines in Australia. By selecting suppliers that adhere to GMP standards and regulatory requirements, Sandoz ensures the quality and safety of the imported products.

3Market Positioning

Based on its product mix, Sandoz Pty Limited serves various segments of the Australian pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's diverse portfolio enables it to meet the needs of different healthcare providers and patients, contributing to the overall accessibility and availability of essential medicines in Australia.

Seller's Guide — How to Become a Supplier to Sandoz Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Sandoz Pty Limited, particularly if they can offer products that align with the company's strategic focus on immunosuppressants, CNS & psychiatric, and respiratory therapeutic categories. By meeting the required quality standards and regulatory approvals, Indian exporters can position themselves as viable partners, potentially expanding their market presence in Australia.

2Requirements & Qualifications

Indian exporters seeking to supply Sandoz Pty Limited and the Australian market must ensure that their products are registered in the ARTG and manufactured in compliance with GMP standards recognized by the TGA. Additionally, they must adhere to Australian labeling requirements, including language and serialization mandates, to facilitate traceability and ensure patient safety.

3How to Approach

Indian exporters interested in supplying Sandoz Pty Limited should initiate contact by demonstrating their compliance with Australian regulatory requirements and highlighting their product offerings in the relevant therapeutic categories. Participating in tenders and engaging in discussions about regulatory filing strategies can facilitate the establishment of a partnership. Understanding the regulatory approval timelines and ensuring adherence to all import conditions are crucial steps in building a successful relationship with Sandoz Pty Limited.

Frequently Asked Questions — Sandoz Pty Limited

What products does Sandoz Pty Limited import from India?

Sandoz Pty Limited imports 7 pharmaceutical products across 5 categories. Top imports: Tacrolimus ($1.9M), Escitalopram ($1.4M), Mycophenolate ($750.0K), Allopurinol ($700.0K), Fluticasone ($650.0K).

Who supplies pharmaceuticals to Sandoz Pty Limited from India?

Sandoz Pty Limited sources from 7 verified Indian suppliers. The primary supplier is Cipla Limited (40.1% of imports, $2.5M).

What is Sandoz Pty Limited's total pharmaceutical import value?

Sandoz Pty Limited's total pharmaceutical import value from India is $6.2M, based on 152 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sandoz Pty Limited focus on?

Sandoz Pty Limited imports across 5 categories. The largest: Immunosuppressants (41.7%), CNS & Psychiatric (21.7%), Respiratory (17.7%).

Get Full Sandoz Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.